ACE inhibition in stable coronary artery disease.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed.

1. Influence of crossover on mortality in a randomized study of revascularization in patients with systolic heart failure and coronary artery disease.Circulation. Heart failure · 2013
   Trial
2. The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in elderly (≥ 65) patients with acute myocardial infarction without hypertension.Heart and vessels · 2023
   Article
3. The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in patients with acute myocardial infarction without hypertension.PloS one · 2020
   Article
4. Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure.European heart journal · 2014
   Article
5. Immunological aspects of atherosclerosis.Seminars in immunopathology · 2014
   Review
6. [Secondary prevention after myocardial infarction].Der Internist · 2008
   Review
7. ACE inhibition in secondary prevention: are the results controversial?Clinical research in cardiology : official journal of the German Cardiac Society · 2006
   Article

Corrections and comments

• Comment on
  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.2000
• Comment on
  Angiotensin-converting-enzyme inhibition in stable coronary artery disease.2004

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as